Single User License: $5500
Member Price: FREE
Use code SUMMER at checkout for 50% OFF
Already a member? Login to access this report free.
Report Highlights
The global market for clinical applications of next-generation sequencing is estimated to increase from $21.9 billion in 2023 to reach $52.9 billion by 2028, at a compound annual growth rate (CAGR) of 19.3% from 2023 through 2028.
Report Includes
- 41 data tables and 237 additional tables
- An overview of the global market for emerging clinical applications of next-generation sequencing
- Analysis of global market trends, featuring historical revenue data for 2020 to 2022, estimates for 2023, as well as forecasts for 2028, including projections of compound annual growth rates (CAGRs) through 2028
- Evaluation of the current market size and revenue growth prospects, accompanied by a market share analysis by disease indication, test complexity, test purpose, application and geographic region
- Discussion of market opportunities for clinical NGS products, clinical applications, industry structure, regulatory scenarios and use of NGS-based diagnostics and technologies
- Coverage of genome mapping programs, technological advances and innovations in NGS platforms, and the Ion Torrent Genexus System from Thermo Fisher Scientific and the Magnis NGS Prep System lfrom Agilent Technologies Inc
- Description of NGS-oriented tests such as non-invasive prenatal testing (NIPT) and pre-implantation genetic testing (PGT), and a discussion of their advantages
- Market share analysis of the key companies and a look at their proprietary technologies, strategic alliances and other key market strategies, plus a patent analysis
- Profiles of the leading players, including Illumina Inc., Thermo Fisher Scientific Inc., QIAGEN, Agilent Technologies Inc., and BGI Genomics
Report Scope
The scope of the report includes clinical NGS technologies, applications, industries, initiatives, patents, and companies. The markets for NGS-based diagnostics are given for the years 2020, 2021, 2022, 2023 and 2028.
This report reviews the main sequencing technologies and explains why genetic variation is important in clinical testing. It then discusses some of the significant research initiatives that impact clinical NGS applications. Liquid biopsy formats are discussed. The main market driving forces are also discussed.
The report examines the markets by test complexity, clinical indication and test purpose. Test complexity refers to the plex level (i.e., the number of genetic markers that can be analyzed within a sample) and coverage (e.g., the extent to which the genome is covered) of the test. Examining the market by test complexity provides valuable insight into which products (e.g., sample preparation, NGS instrument, informatics, etc.) will be in demand in the future.
The report provides market data and forecasts for NGS diagnostics by specific applications, including those for oncology, cardiovascular diseases, clinical microbiology/infectious diseases, Mendelian disorders, metabolic/immune disorders, neurological disorders, reproductive health, and transplant medicine.
Specific geographic markets are discussed, namely North America, Europe, Asia-Pacific, and the Rest of the World.
Industry sectors analyzed include DNA sequencing instruments; long-read sequencing; sequencing informatics; target enrichment; CTC capture and detection; liquid biopsy; cancer screening/early detection; direct-to-consumer testing; and noninvasive prenatal testing.
More than 100 companies in the clinical NGS industry are profiled in this report.
BCC Research also provides a summary of the recent, primary industry acquisitions and strategic alliances, including key alliance trends.
Report Synopsis
| Report Metrics | Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Base year considered | 2022 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Forecast period considered | 2023-2028 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Base year market size | $18.4 billion | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market size forecast | $52.9 billion | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Growth rate | CAGR of 19.3% for the forecast period of 2023-2028 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Units considered | $ Millions | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Segments covered | Disease Class, Test Complexity, Analysis Type, and Geographic Region | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Regions covered | North America, Europe, Asia-Pacific, and Rest of the World | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Countries covered | Austria, Belgium, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Iceland, Italy, Luxembourg, Netherlands, Norway, Poland, Portugal, Romania, Spain, Switzerland, Turkey, UK, Sweden, Australia, China, India, Japan, Malaysia, New Zealand, Philippines, Singapore, Taiwan, Thailand, South Korea, Argentina, Brazil, Chile, Israel, Kuwait, Russia, Saudi Arabia, South Africa, UAE | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Key Market Drivers |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Companies studied |
|
Frequently Asked Questions (FAQs)
Analyst Credentials
BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.
Consulting Editor’s Credentials
Dr. Marianna Tcherpakov has more than 10 years of experience as a bench scientist specializing in the areas of biochemistry, cell biology, assay development, antibody and drug manufacturing. She has authored several scientific publications in peer review journals. In the last 10 years, Marianna worked as a business development professional in CRO/CDMO industry. She is familiar with pharmaceutical and biotech landscape, trends and potential future developments in industry.
Report Highlights
The global market for clinical next-generation sequencing (NGS) should grow from $5.9 billion in 2020 to $22.9 billion by 2025 with a compound annual growth rate (CAGR) of 31.4% for the period of 2020-2025.
Report Includes
- 29 data tables and 73 additional tables
- An updated review of the global market for emerging clinical applications of the next-generation sequencing (NGS) based diagnostics and related technologies
- Analyses of the global market trends, with data from 2019-2020, and projections of compound annual growth rates (CAGRs) through 2025
- Discussion of market opportunities for clinical NGS products, clinical applications, industry structure, regulatory scenario, and penetration of NGS-based diagnostics and technologies within the industry
- Estimation of the current market size and revenue forecasts for the global NGS diagnostic markets, and corresponding market share analysis by disease indication, test complexity, test purpose, application and geographic region
- Evaluation of the key NGS workflow portions of the industry (e.g., sequencing instruments, pre-sequencing target preparation and capture, and post-sequencing data analysis) and the main clinical indications where NGS will capture significant market share by 2025
- Assessment of main sequencing technologies and explanation of the importance of genetic variation in clinical testing as well as some of the significant research initiatives affecting clinical NGS applications
- A summary of the major acquisitions and strategic alliances in the clinical NGS industry from January 2019 through April 2021, including key alliance trends
- Patent review and significant allotments of the U.S. patents in the liquid biopsy industry
- Company profiles of the major market players, including Agilent Technologies Inc., Becton, Dickinson and Co. (BD), Koninklijke Philips N.V., Merck KGaA, Novogene Co. Ltd., Oxford Nanopore Technologies Ltd., Qiagen NV, Roche Holding AG, and Thermo Fisher Scientific Inc.
Report Highlights
The global clinical next-generation sequencing (NGS) market reached $2.7 billion in 2016. This market is expected to grow at a compound annual growth rate (CAGR) of 27%, from nearly $3.2 billion in 2017 to $10.5 billion by 2022.
Report Includes
- An overview of the global market for next-generation sequencing and its emerging clinical applications.
- Analyses of global market trends, with data from 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022.
- Examination of the sequencing industry structure for key market segments.
- Discussion covering the strategies employed by the main companies in the market.
- Comprehensive company profiles of major players in the field.
Report Highlights
The global clinical next-generation sequencing (NGS) market was valued at $886.1 million in 2014. This market is expected to grow at a compound annual growth rate (CAGR) of 31.3%, from $997.1 million in 2015 to nearly $3.9 billion by 2020.
Report Includes
- An overview of the global market for next-generation sequencing and its emerging clinical applications.
- Analyses of global market trends, with data from 2014, estimates for 2015, and projections of CAGRs through 2020.
- Examination of the sequencing industry structure for key market segments.
- Discussion covering the strategies employed by the main companies in the market.
- Comprehensive company profiles of major players in the field.
Report Highlights
The next generation sequencing market reached $231.7 million in 2012. The market is expected to reach $510.7 million in 2013 and $7.6 billion in 2018 for a compound annual growth rate (CAGR) of 71.6%.
Report Includes
- An overview of the global market for next-generation sequencing and its emerging clinical applications
- Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018
- Examination of the sequencing industry structure for the key market segments, as well as strategic alliances and acquisitions, as well as evaluations of sequencing patents
- Discussion of the strategies of the main companies in the market
- Comprehensive company profiles of major players in the field
Related Reports
Life Science Tools and Reagents: Global Markets
The global market for life science tools and reagents, including COVID-19 diagnostics was valued at $59.4 billion in 2023. This market is expected to grow from $53.2 billion in 2024 to reach $66.5 billion by the end of 2029, at a CAGR of 4.6% during the forecast period of 2024-2029.
Exosome Diagnostics, Therapeutics and Research Tools: Global Markets
The global market for exosome diagnostics, therapeutics and research tools is estimated to increase from $227.5 million in 2023 to reach $1.3 billion by 2028, at a compound annual growth rate (CAGR) of 42.2% from 2023 through 2028.
Next-Generation Cancer Diagnostics: Technologies and Global Markets
The global next-generation cancer diagnostics market reached $8.7 billion in 2022 and should reach $15 billion by 2027, with a compound annual growth rate (CAGR) of 11.5% during the forecast period of 2022-2027.
Proteomics: Technologies and Global Markets
The global proteomics market should reach $55.1 billion by 2027 from $27.1 billion in 2022 at a compound annual growth rate (CAGR) of 15.3% for the forecast period of 2022 to 2027.
Recent Reports
Life Science Tools and Reagents: Global Markets
The global market for life science tools and reagents, including COVID-19 diagnostics was valued at $59.4 billion in 2023. This market is expected to grow from $53.2 billion in 2024 to reach $66.5 billion by the end of 2029, at a CAGR of 4.6% during the forecast period of 2024-2029.
RNAi Technologies and Global Markets
The global market for RNAi technology is estimated to increase from $2.1 billion in 2023 to reach $4.8 billion by 2029, at a compound annual growth rate (CAGR) of 14.8% from 2024 through 2029.
Metabolomics: Technologies and Global Markets
The global market for metabolomics technologies is expected to grow from $16.4 billion in 2024 and is projected to reach $30.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 13.1% during the forecast period of 2024 to 2029.
Global Recombinant Proteins Market
The global market for recombinant proteins is estimated to increase from $132.4 billion in 2023 to reach $203.6 billion by 2029, at a compound annual growth rate (CAGR) of 7.5% from 2024 through 2029.
Polymerase Chain Reaction (PCR) for Point-of-Care (POC) Diagnostics
The global market for polymerase chain reaction for point-of-care diagnostics is expected to grow from $1.6 billion in 2024 to $2.1 billion by the end of 2029, at a compound annual growth rate (CAGR) of 5.9% from 2024 through 2029.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More